Allergen Research Corporation Expands Management with New VP Functions by longitudeadmin | Apr 8, 2015 | Portfolio News
Warrant Exercises Generate $17.2 Million; Proceeds to Advance Next-Generation Compounds and Support Commercialization of Korlym. by longitudeadmin | Apr 1, 2015 | Portfolio News
CardioDx Announces Positive Results from Clinical Utility Study Evaluating the Corus CAD Blood Test’s Influence on Clincial Decision Making in the Assessment of Obstructive Coronary Artery Disease in Women by longitudeadmin | Apr 1, 2015 | Portfolio News
Esperion Therapeutics Announces Closing of Follow-On Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares of Common Stock. by longitudeadmin | Mar 24, 2015 | Portfolio News
Allergen Research Corporation Completes $80 Million Series B Financing to Advance Drug Development Portfolio for Food Allergy by longitudeadmin | Mar 12, 2015 | Portfolio News
